Thursday 11 June 2020

The Brewery, London EC1


2014 Voting Panel


Ian Restall

Flathill Communications plc
Voting Panel Chairman

Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding The Design Portfolio Marketing Services in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society.


Mary Clark

Hume Brophy

Mary is head of Hume Brophy’s International Healthcare IR & PR practice.

She has over 20 years’ experience in strategic corporate and financial communications. She specialises in advising healthcare companies on all aspects of their financial and corporate communications. She has a wealth of experience in corporate positioning, M&A, IPOs and fund raisings. She has worked with over 30 healthcare clients across ten European countries.

Mary was previously Head of Healthcare at Capital MS&L. Prior to this she was Head of the European Consulting team at Thomson Reuters, the world’s largest investor relations company, where she advised a large number of companies on investor relations strategies, and all aspects of corporate and financial communications. She started her career at BTG plc where she was Director of Corporate Communications and Investor Relations.

Mary has been regularly highly ranked in the top professionals in the Extel investor relations survey voted by leading institutional investors and sell-side analysts.



Jessica Coles

Design Portfolio

Jessica is Head of Client Services at Design Portfolio, responsible for ensuring consistency and quality across the client services team, helping to develop long term relationships with clients, as well as a focus on the monitoring of best practice. She is a member of the IR Society and holds the IR Society’s Certificate in Investor Relations.



Victoria Darbyshire 

JP Morgan 

Click here to see an interview with Victoria 

Victoria joined JP Morgan Asset Management in the European Research team covering the healthcare sector seven years ago after starting in the investment bank in 2004. She also contributes to the JP Morgan Global Healthcare Fund. Victoria achieved a top three ranking in the 2013 Extel buyside survey in both the Pharma & Biotech and Medtech sectors. She became a CFA charterholder in 2009 and has a BSc in Chemistry from Durham University.



Mary-Jane Elliott

Consilium Strategic Communications

Mary-Jane Elliott co-founded Consilium Strategic Communications in 2013 and is an expert in stakeholder communications for international and domestic healthcare companies. She possesses more than 15 years of experience in the healthcare industry from leading agencies and in-house pharma roles. Prior to founding Consilium, Mary-Jane established and led M:Communications’ successful international healthcare team where she advised public and private companies internationally across all sub-sectors of healthcare and including some of the sector’s leading industry bodies. She has a broad range of experience including advising on a wide range of IPOs, secondary fundraisings, private equity placements, M&A transactions and crisis communications. Mary-Jane worked at the FTSE250 company, PowderJect Pharmaceuticals, where she initially worked in R&D and latterly became a member of the Corporate Communications and Investor Relations team prior to the Company's sale to Chiron for £550M in 2003. As a healthcare specialist, Mary-Jane has a BSc (Hons) in BioMedical Sciences.



Stefan Hamill

Peel Hunt

Stefan joined Peel Hunt in January 2011, joining forces with Paul Cuddon to form what Peel Hunt believes is the strongest team in UK healthcare and life sciences. Prior to joining Peel Hunt, Stefan was a founder of independent research house Clear Capital (now part of Espirito Santo) where he covered a wide variety of firms across the sector and was ranked No.3 in Extel. Stefan was formerly a strategy consultant and has a PhD in Antibody Engineering from the University of Cambridge.


Oscar Izeboud

Kempen & Co

Oscar joined Kempen & Co, a merchant bank based in Amsterdam, in 2006. He is currently Managing Director Corporate Finance, heading the Life Sciences/Healthcare team. Prior to this Oscar worked as Director Equity Research, covering European listed life sciences companies at Kempen & Co. Oscar has advised on a wide variety of primary and secondary public offerings and M&A transactions across Europe. Before Kempen & Co he worked in various commercial roles in the industry, eventually in business development at Crucell. Oscar obtained his PhD in Pharmacology at TNO in the Netherlands and he holds an MSc degree in Biopharmaceutical Sciences from the University of Leiden.


Mike Mitchell

Panmure Gordon & Co

Mike joined Panmure Gordon in November 2012, strengthening an already established healthcare team. His coverage focuses on small/mid-cap medtech and life science companies, and he is a three-time No.1-ranked Starmine Award winner. Prior to joining Panmure, he spent three years at Seymour Pierce, where he helped to build the medtech sector franchise into one of the leading small cap teams in London. Formerly an analyst with Oriel Securities and Teather & Greenwood, he commenced his City career with Evolution Capital in 2001. Mike’s technical background is underpinned by his career as a research scientist including postdoctoral appointments in the US (Bloomington) and UK (Imperial College), having gained his PhD in Chemistry in 1997 (Leeds).



Geraldine O'Keeffe

Life Sciences Partners
Click here to see an interview with Geraldine

Geraldine, Partner, joined LSP as a Senior Investment Manager in 2008. Prior to joining LSP, she held the position of senior sell-side analyst at Fortis, where she focused exclusively on the global biotechnology industry. While at Fortis, she initiated and maintained coverage on a wide range of biotechnology companies and was actively involved in several IPOs. Before joining the investment community, Geraldine worked for Biotrin (now part of Diasorin) and was instrumental in gaining FDA approval for several diagnostic tests. She also lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a BSc Biochemistry/Microbiology from University College Cork, an MSc in Biotechnology from University College Galway, Ireland and conducted post-graduate research at the Max Planck Institute for Biophysical Chemistry and Oxford University. She is also a graduate of The Dublin School of Business.


Professor Alan M. Palmer FSB, PhD, MSc, BSc

Cerebroscience Ltd

Alan Palmer’s career has focussed on neurodegenerative disorders and their treatment. He obtained his first degree in Biochemistry from the University of Warwick, with MSc and PhD degrees from the University of London. He has over 25 years of medicines research experience, starting as a Principal Investigator at both the Alzheimer’s disease Research Centre and the Head Injury Research Centre at the University of Pittsburgh. He worked for Wyeth Research before co-founding Cerebrus Ltd (which later became Vernalis Ltd) and then Pharmidex Pharmaceutical Services Ltd. In 2005 the London Biotechnology Network voted him ‘entrepreneur of the year’. He has published over 100 manuscripts, 32 of which have been highly cited (>50 citations) and is a visiting Professor at the School of Pharmacy in London, a Fellow of the Society of Biology and a former Chairman of the Society for Medicines Research; he is also a member of the Scientific Advisory Board of GE Healthcare Medical Diagnostics and has served as a member of the Government’s Biotechnology & Pharmaceuticals Sector Advisory Group.



Gareth Powell

Polar Capital

Gareth joined Polar Capital in 2007 to set up the healthcare team. He has over 12 years' investment experience in the healthcare sector, with ten years as a Portfolio Manager. He joined Framlington in 1999 becoming a portfolio manager on the Framlington Health fund. In 2002, he helped launch and then run the Framlington Biotech Fund. Gareth became a CFA charter holder in 2003. Gareth studied biochemistry at Oxford from 1995 to 1999 and during that time worked at Astellas, the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and the Oxford Business School.


Nick Rodgers

Chairman, Oxford BioMedica
Click here to see an interview with Nick

Nick is an experienced non-executive director and chairman with a background as a successful corporate financier. He has considerable experience of businesses in the healthcare, medical, biotechnology environmental and technology sectors.

Nick is Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company. Nick is also chairman of SEHTA Enterprises, the commercial arm of SEHTA, one of the largest health technology networking organisations in the UK. Until March 2013 Nick was the Chief Executive of Ipso Ventures plc, a creator and investor in early stage technology and healthcare businesses. As such he created eight businesses around university technology.



Julie Simmonds

Canaccord Genuity

Julie joined Canaccord Genuity when it acquired Collins Stewart in December 2010. Her research coverage focuses on small and mid-cap healthcare companies. Julie joined from Piper Jaffray where she spent five years as a Senior Analyst in the No.1 Extel rated healthcare team. Her research coverage included both small and mid-cap UK healthcare companies, including medical devices, biotechnology and services, and large-cap European stocks. Prior to Collins Stewart Julie was with Nomura and previously Head of Life Sciences Research at Evolution Securities where she was an analyst from 1998 to 2004. Julie has a PhD in Microbiology from University of Kent at Canterbury. Prior to becoming an analyst Julie gained industrial experience in both Europe and the US.


Sachin Soni

Kempen & Co

Sachin currently works as Director Equity Research (Life Sciences) at Kempen & Co where he is responsible for coverage of European healthcare/life sciences sector. He has over eight years of experience in the life sciences industry with an exposure to both private (venture capital) as well as public market investments and has been involved in multiple IPOs/secondary placements. Sachin started his career as a medical doctor where he worked as a general practitioner with the Indian Red Cross and Max Healthcare Hospital. He was ranked among top 0.1% students at All-India level in Physics and Chemistry and finished his degree in Medicine (MBBS) with honors in Pharmacology and Biochemistry from Seth G S Medical College & KEM Hospital, Mumbai, India. He holds a Master's in Business Administration with concentration in finance from Rotterdam School of Management, the Netherlands/Columbia Business School, US.



Dr Ivo Staijen, CFA

HBM Partners AG
Click here to see an interview with Ivo

Ivo joined HBM Partners in 2003 as Investment Advisor for the biotechnology and pharma sector. HBM Partners is the advisor to several healthcare funds, the best-known being HBM Healthcare Investments. Prior to HBM Partners, Ivo worked as biotechnology analyst at Bank Sarasin, and before that as a Department Head at MDS Pharma Services Switzerland. Ivo studied chemistry at the University of Groningen, the Netherlands, and was a visiting scholar at the Department of Biology at MIT in 1991. He obtained his PhD in Biology from the ETH in Zurich, Switzerland, in 1996. He has over 13 years' experience in Investment Management and Research, and is a CFA Charter Holder since 2004.



Melanie Toyne-Sewell

Instinctif Partners

Melanie is a specialist in financial and corporate communications for life science companies and heads up Financial PR for the life sciences team. Prior to Instinctif Partners, Melanie was Head of Healthcare at the Hogarth Partnership, a partner in the Financial Dynamics Life Sciences team and a Director of Merlin Financial. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare sectors. Before entering the field of financial PR, Melanie was at Price Waterhouse where she qualified as a chartered accountant. She has a BA Hons in Biochemistry from Oxford University.


Elise Wang

Click here to see an interview with Elise

As a Principal and Analyst on the Private Transactions team, Elise provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Prior to joining Deerfield in 2010, Elise began her career in healthcare in 1987 as a venture capitalist and banker at PaineWebber Inc. and was an officer of PaineWebber Development Corporation, which managed nearly $1.0bn in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies. From 1996 to 2007, Elise was a Senior Research Analyst and Managing Director in healthcare primarily covering the biotechnology industry at PaineWebber Inc. (1996-2001) and Citigroup (2001-2007). She holds an AB in Engineering Sciences with a specialty in Biomechanics from Harvard University and an MBA from Harvard Business School.


Brian White

Shore Capital

Brian is Head of Healthcare at Shore Capital covering the entire spectrum of UK healthcare companies including life sciences, large pharma, medical devices, medical technology and healthcare services. Prior to joining Shore, Brian led the pan-European biotechnology research effort latterly as a Managing Director at Deutsche Bank. Brian has been involved in capital raisings for companies throughout Europe and has been highly ranked in various external surveys including Institutional Investor, Extel and Starmine.